Company / PP&E (Net)
Janux Therapeutics, Inc. PP&E (Net) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$3.9M
FY2025
5-year range
$1.4M / $7.1M
FY2021-FY2025
Trend
-20.8%
vs FY2024
Sector context
#119 of 195
Health Care
What the data says
At $4M, Janux Therapeutics, Inc.'s pp&e (net) ranks #119 of 195 in the Health Care sector. PP&E (Net) has declined for 3 consecutive years, from $7M in FY2022 to $4M in FY2025.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of +90.1%.
Declined from $7M to $4M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -18.4%
- 5-Year CAGR
- +90.1%
- 10-Year CAGR
- -
Sector benchmark
#119 of 195 in Health CareTop 61% of 195This company $3.9M Sector average $770.1M
▼
-99.5% below sector average
Key checks
Key Insights
- Janux Therapeutics, Inc.'s pp&e (net) has declined for 3 consecutive years.
- 5-year CAGR of +90.1%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 20.8% year-over-year.
- Ranks #119 out of 195 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 9.17 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.9M | -20.8% |
| FY2024 | $4.9M | -30.5% |
| FY2023 | $7.0M | -1.2% |
| FY2022 | $7.1M | +401.8% |
| FY2021 | $1.4M | +811.0% |
| FY2020 | $155.0K | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026